Figure 1 (Figure01)
Lotronex Tablet
Product Images NDC 83107-012
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Lotronex (NDC 83107-012). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Legacy Pharma Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Principal Display Panel (Lotronex 0.5 mg Bottle Label)
This text provides information about the medication LOTRONEX (alosetron hydrochloride) Tablets and emphasizes the federal law requirement for dispensing the tablets with an attached Medication Guide. The text also includes the manufacturer's contact information and mentions that the medication contains 5mg of alosentron hydrochloride. The tablets are manufactured in Canada.*
Principal Display Panel (Lotronex 1 mg Bottle Label)
This text provides information about a medication called LOTRONEX in the form of tablets containing alosetron hydrochloride. It includes details on dosage, administration, storage requirements, and dispensing regulations. The tablets contain 1 mg of alosetron hydrochloride and are distributed by Legacy Pharma USA Inc. The product is required to be dispensed with a Medication Guide attached, per federal law. Storage instructions indicate keeping the tablets at a controlled room temperature.*
Image Description (Logo)
Chemical Structure (Lotronex Structure)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
